Abstract
Health-related quality of life (HRQoL) is an important outcome within early benefit assessment (EBA) of new oncological medicines in German HTA. The study examines the extent to which results on HRQoL presented are based on robust evidence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
